Co-Diagnostics Inc. (NASDAQ: CODX) received formal notice from The Nasdaq Stock Market LLC on March 9, 2026, confirming the company has regained compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, according to a company statement.

The molecular diagnostics company met the $1.00 bid price rule and other listing requirements, resulting in the closure of a previously disclosed listing matter. Co-Diagnostics shares will resume trading on Nasdaq effective March 11, 2026.

The Salt Lake City-based company develops molecular diagnostic tests using a proprietary platform for detecting and analyzing nucleic acid molecules. Co-Diagnostics is working on clinical performance studies and regulatory clearance pathways for its Co-Dx PCR point-of-care diagnostics platform, which includes PCR Home, PCR Pro, and associated mobile applications.

The Co-Dx PCR platform remains subject to review by the FDA and other regulatory bodies and is not currently available for sale. The company uses its technology to design tests for identifying genetic markers in applications beyond infectious disease detection.

Co-Diagnostics manufactures diagnostic technologies from its Utah headquarters and markets products designed for nucleic acid molecule analysis.